Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, and is the principal inventor of the patented L-glutamine therapy for treatment of sickle cell disease. He is a cofounder of Emmaus, principal investigator for LABioMed at Harbor-UCLA Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA. His experience includes serving as President, Chief Executive Officer and Medical Director of Hope International Hospice. A board-certified by the American Board of Internal Medicine and the American Board of Internal Medicine/Hematology, Dr. Niihara is licensed to practice medicine in both the U.S. and Japan. His honors include the Life Time Achievement Award, from the Sickle Cell Disease Foundation of California and the Abigail Kawananako Award. Dr. Niihara received his B.A. in Religion from Loma Linda University and obtained his M.D. degree from the Loma Linda University School of Medicine.
Sickle cell disease - Cancer & Carcinogenesis - Blood & Blood Products & Transfusions - Biological markers and Oncology Specialized Techniques in Research: - Red cell enzyme studies - Red cell nucleotide analysis
Research Article: Clin Pharmacol Biopharm 2014, 3:116
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals